Gustavo Alameda, MD
Neurology · Fort Lauderdale, FLNPI 1225233521
Payments from drug & device makers
Across 27 payments — averaging $3599.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$54K
- PTC Therapeutics, Inc.$23K
- Amylyx Pharmaceuticals, Inc.$12K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Novartis$188
- Life Molecular Imaging Ltd$23
What the payments were for
- Speaking & faculty fees$4,05096%
- Food & beverage$1714%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 5 | $54,108 |
| PTC Therapeutics, Inc. | 10 | $22,973 |
| Amylyx Pharmaceuticals, Inc. | 9 | $11,837 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $8,049 |
| Novartis | 1 | $188 |
| Life Molecular Imaging Ltd | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELYVRIO$4,050
How this compares
$97,178 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 46 | $633,019 |
| Kesimpta PenOfatumumab | 15 | $144,797 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $22,106 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $22,013 |
| Dalfampridine ErDalfampridine | 26 | $10,777 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,381 |
| FingolimodFingolimod Hcl | 11 | $6,196 |
| Riluzole | 18 | $3,063 |
| Pregabalin | 52 | $1,133 |
| Pyridostigmine Bromide | 11 | $1,010 |
| Gabapentin | 35 | $793 |
| Baclofen | 37 | $745 |
| Memantine Hcl | 12 | $292 |
| Celecoxib | 14 | $221 |
| Prednisone | 20 | $185 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fort Lauderdale
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.